OBJECTIVES: To establish and analyse treatment satisfaction and principal causes which result in termination of drug treatment of Parkinson's Disease (PD) in Russia. METHODS: The retrospective analysis was carried out for treatment which patients received. In the analysis, 241 patients with PD (male: 127, female: 114; mean age: 66.1 ± 7.5 years, duration of disease: 5.2 ± 3.2 years) have been included. RESULTS: Majority of patients received two or three drugs; 160 patients accepted levodopa (mean dose: 612.0 ± 327.7mg daily); 105 patients accepted anticholinergics such as trihexyphenidyl (mean dose: 5.0 ± 2.0mg); 83 patients accepted amantadine (mean dose: 253.9 ± 72.1mg); 41 patients accepted dopamine agonist such as pramipexole (mean dose: 2.4 ± 1.0mg); and 35 patients accepted selegiline (mean dose: 9.1 ± 3.2mg). Adverse events resulted in termination of treatment more often for anticholinergics (n=32), less often for levodopa (n=8), amantadine (n=5) and pramipexole (n=4). Insufficient efficacy was the most often cause of end in treatment by trihexyphenidyl (n=21), selegiline (n=17), amantadine (n=15), and rare reason of end of treatment by levodopa (n=3), pramipexole (n=2). High cost of drugs was the most often reason of pramipexole (n=27) cancellation and only one case led to cancellation of levodopa. In other cases, patients were satisfied with the treatment. In Russia, mean daily dose of levodopa costs about US$0.9, pramipexole - US$3.96, selegiline - US$0.88, amantadine - US$0.05 and trihexyphenidyl - US$0.02. CONCLUSIONS: Principal causes of the termination of drug treatment of PD were adverse events, insufficient efficiency, and high cost. Reduction of cost of treatment of dopamine agonists such as pramipexole could lead to increase in number of PD patients who would continue to get treated in Russia.